Dopaminergic Neuron Progenitor Cell Selection Using Corin and Lrtm1
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing dopaminergic neuron progenitor cells for Parkinson's disease treatment face challenges such as ethical concerns, high risk of infection, formation of benign tumors, dyskinesia, lot-to-lot variability, and high costs, with existing marker selection methods needing improvement.
Innovation Solution
A method involving adherent culture of pluripotent stem cells using specific reagents on an extracellular matrix, followed by selection and suspension culture of Corin- and/or Lrtm1-positive cells, utilizing markers like Corin and Lrtm1 to enhance survival and efficiency of dopaminergic neuron progenitor cell production.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If fetal mesencephalic grafting is used for Parkinson's disease treatment, then therapeutic effect is achieved, but ethical problems arise and infection risk increases
Solution Approach 1:
The patent uses pluripotent stem cells as a copy substitute for fetal mesencephalic tissue. Instead of directly transplanting fetal cells, the invention generates dopaminergic neuron progenitor cells from pluripotent stem cells in vitro, then transplants these cultured cells. This copying approach eliminates ethical issues and infection risks associated with fetal tissue while maintaining therapeutic effectiveness.
Solution Approach 2:
The patent introduces pluripotent stem cells as an intermediary between the desired therapeutic outcome and the source material. Rather than directly using fetal mesencephalic tissue, the invention uses pluripotent stem cells as a mediator that can be ethically sourced, cultured, and differentiated into the needed dopaminergic neurons, thereby resolving the ethical and safety contradictions.
2Device complexity
If neural cells are transplanted without careful selection, then transplantation process is simplified, but formation of benign tumors and dyskinesia occurs
Solution Approach 1:
The patent performs preliminary selection and differentiation of neural cells before transplantation. By using marker genes to identify and select dopaminergic neuron progenitor cells in advance, and by controlling differentiation in vitro, the invention ensures that only appropriate cells are transplanted. This preliminary action prevents tumor formation and dyskinesia while maintaining a manageable transplantation process.
Solution Approach 2:
The patent employs marker gene expression as a feedback mechanism to monitor and control cell differentiation and selection. By detecting specific marker genes that indicate dopaminergic neuron progenitor cell identity, the invention can selectively harvest and transplant only the desired cell population, preventing harmful outcomes while maintaining process efficiency.
3Difficulty of detecting and measuring
If existing marker selection methods are used, then cell selection is possible, but selection process needs improvement and survival rate is insufficient
Solution Approach 1:
The patent changes the selection parameters by using specific marker genes (such as those indicating dopaminergic neuron progenitor cell identity) and optimizing culture conditions including specific growth factors and differentiation inducers. This parameter optimization improves both the precision of cell selection and the survival rate of transplanted cells, overcoming the limitations of existing methods.
4Productivity
If conventional production methods are used, then dopaminergic cells can be produced, but lot-to-lot variability increases and costs increase
Solution Approach 1:
The patent segments the cell production process into distinct, controlled stages: pluripotent stem cell culture, differentiation induction using specific factors, marker-based selection, and expansion culture. This segmentation allows each stage to be optimized and standardized independently, reducing lot-to-lot variability while maintaining high productivity.
Solution Approach 2:
The patent standardizes critical parameters including growth factor concentrations, differentiation induction conditions, and culture medium compositions. By controlling these parameters consistently across production batches, the invention reduces lot-to-lot variability while maintaining efficient cell production and reducing costs through optimized resource usage.
Data Source
AI summary
The present invention provides a method for producing dopaminergic neuron progenitor cells from pluripotent stem cells, which method comprises the steps of: (i) performing adherent culture of pluripotent stem cells on an extracellular matrix in a medium containing a reagent(s) selected from the group consisting of BMP inhibitor, TGFβ inhibitor, SHH signal-stimulating agent, FGF8, and GSK3β inhibitor; (ii) collecting Corin- and/or Lrtm1-positive cells from the cells obtained in Step (i) using a substance which binds to Corin and/or a substance which binds to Lrtm1; and (iii) performing suspension culture of the cells obtained in Step (ii) in a medium containing a neurotrophic factor.